Tag: Crohn’s Disease

1. At weeks 10 and 58, more patients in the filgotinib 200 mg group experienced clinical remission compared with the placebo group. 2. The proportion of patients with treatment-related side effects was similar between filgotinib 100 mg, filgotinib 200 mg, and placebo. Evidence Rating Level: 1 (Excellent) Study Rundown: Ulcerative colitis (UC)...

1. Carriage of the HLA-DQA1*05 allele is significantly associated with the development of antibodies against anti-TNF agents. Evidence Rating Level: 2 (Good) Anti-tumor necrosis factor (anti-TNF) therapies are the most widely used biologics for treating immune-mediated diseases. However, repeated administration can lead to the formation of anti-drug antibodies (immunogenicity), which can...

In patients with Crohn’s disease (CD), endoscopic evidence of healing after treatment is associated with favorable outcomes. Anti-tumor necrosis factor (TNF) agents have been shown to induce ileocolonic healing in CD, however the impact of these agents on gross small bowel healing as indicated by endoscopy has not been...

Evaluation of the Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple Sclerosis Diagnosing multiple sclerosis (MS) is challenging, in part because imaging findings in MS partially overlap with MS mimics such as vascular disease, migraine, and neuromyelitis optica spectrum disorder (NMOSD). The central vein sign has been shown...

Anti-tumor necrosis factor (TNF) therapies are commonly used in the treatment of patients with moderate to severe Crohn’s disease. However, due to the high costs of anti-TNF medications, biosimilar medications are being developed. These drugs have high likeness to already licensed biological therapies and are subject to strict approval...

1. The biosimilar to infliximab, CT-P13 was shown in this study to have equivalent efficacy to the anti tumor-necrosis factor (TNF) monoclonal antibody for Crohn’s treatment. 2. There was no significant safety differences observed in this study between the two treatments for Crohn’s disease. Evidence Rating Level: 2 (Good) Study Rundown: Crohn’s...

1. Repeated gastrointestinal infections in mice, in this case Salmonella enterica Typhimurium (ST), caused intestinal tissue inflammation which escalated with repeated infections. 2. Increased turnover of intestinal alkaline phosphatase (IAP), related to increased endogenous neuraminidase activity among duodenal enterocytes, was found to be associated with inflammatory bowel disease (IBD). The...

1. In this retrospective cohort study, inflammatory bowel disease (IBD) patients on anti-tumor necrosis factor (TNF) agents or thiopurines had a higher rate of developing lymphoma compared to non-exposed IBD patients. 2. The combination of both anti-TNF agents and thiopurines resulted in a higher risk or lymphoma than either alone. Evidence...

1. This systematic review and meta-analysis demonstrated the high diagnostic performance of magnetic resonance (MR) enterography in the diagnosis of active inflammation in pediatric inflammatory bowel disease (IBD). 2. There was substantial heterogeneity, some of which was unexplained, in the original studies which limits the reliability of this study. Evidence Rating...

1. Ustekinumab achieved successful clinical induction in a greater proportion of patients with moderate to severe Crohn’s disease (CD) compared to placebo in two separate lead-in induction randomized controlled trials. 2. In a separate randomized controlled study, subcutaneous ustekinumab was linked with successful maintenance of remission of CD in ustekinumab-responders...